1nKemia IUCT Group Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on 1nKemia IUCT Group's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs Industry Growth | -7.2% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2021 |
Recent past performance updates
No updates
Recent updates
In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, 1nKemia IUCT Group has not provided sufficient past data to assess its track record.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.
Show sectionRevenue & Expenses BreakdownBeta
How 1nKemia IUCT Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 21 | 0 | 0 | 0 | 0 |
| 31 Dec 20 | 0 | -3 | 0 | 0 |
| 31 Dec 19 | 2 | 4 | 2 | 0 |
| 31 Dec 18 | 5 | -24 | 3 | 0 |
| 30 Jun 18 | 6 | -1 | 4 | 0 |
| 31 Mar 18 | 5 | -1 | 3 | 0 |
| 31 Dec 17 | 5 | -1 | 3 | 0 |
| 30 Sep 17 | 3 | -1 | 3 | 0 |
| 30 Jun 17 | 2 | -1 | 3 | 0 |
| 31 Mar 17 | 2 | -1 | 3 | 0 |
| 31 Dec 16 | 2 | 0 | 3 | 0 |
| 30 Sep 16 | 1 | 0 | 2 | 0 |
| 30 Jun 16 | 0 | 0 | 2 | 0 |
| 31 Mar 16 | 1 | 0 | 2 | 0 |
| 31 Dec 15 | 2 | 0 | 2 | 0 |
| 30 Sep 15 | 2 | 0 | 2 | 0 |
| 30 Jun 15 | 2 | 0 | 2 | 0 |
| 31 Mar 15 | 2 | 1 | 2 | 0 |
| 31 Dec 14 | 2 | 1 | 2 | 0 |
| 31 Dec 13 | 2 | 1 | 2 | 0 |
Quality Earnings: Insufficient data to determine if IKM has high quality earnings.
Growing Profit Margin: Insufficient data to determine if IKM's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if IKM's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare IKM's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if IKM's earnings growth over the past year exceeded the Biotechs industry average.
Return on Equity
High ROE: IKM has a negative Return on Equity (0%), as it is currently unprofitable.